N-<2-(4-Morpholinyl)-ethyl>-4-methylbenzamid | 92374-41-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-<2-(4-Morpholinyl)-ethyl>-4-methylbenzamid
• 英文别名: 4-methyl-N-(2-morpholin-4-yl-ethyl)-benzamide；4-methyl-N-[2-(morpholin-4-yl)ethyl]benzamide；4-methyl-N-(2-morpholin-4-ylethyl)benzamide
• CAS: 92374-41-9
• 化学式: C₁₄H₂₀N₂O₂
• mdl: MFCD01212049
• 分子量: 248.325
• InChiKey: AOHGCHQCJQQGKM-UHFFFAOYSA-N

物化性质

• 熔点：
  118-119 °C
• 沸点：
  433.9±40.0 °C(Predicted)
• 密度：
  1.093±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-(2-氨基乙基)吗啉 、 对甲基苯甲酰氯 以 乙醚 为溶剂， 生成 N-<2-(4-Morpholinyl)-ethyl>-4-methylbenzamid
  参考文献：
  名称：

  Loefgren,N.; Wahlstam,H., Acta Chemica Scandinavica (1947), 1961, vol. 15, p. 1467 - 1476

  摘要：

  DOI：

文献信息

• NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN, ETC
  申请人：Rhizen Pharmaceuticals SA

  公开号：US20150057309A1

  公开（公告）日：2015-02-26

  The present invention provides compounds useful as c-Met protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of c-Met kinase mediated disease or disorders with them.

  本发明提供了作为c-Met蛋白激酶调节剂有用的化合物，以及制备它们的方法，含有它们的药物组合物，以及使用它们进行治疗、预防和/或改善c-Met激酶介导的疾病或疾病的方法。
• NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES
  申请人：MUTHUPPALANIAPPAN Meyyappan

  公开号：US20110281865A1

  公开（公告）日：2011-11-17

  The present invention provides, inter alia, compounds of formula I as protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

  本发明提供了一种公式I的化合物作为蛋白激酶调节剂，以及它们的制备方法、含有它们的药物组合物，以及利用它们治疗、预防和/或改善激酶介导的疾病或紊乱的方法。
• HETERO RING-FUSED IMIDAZOLE DERIVATIVE HAVING AMPK ACTIVATING EFFECT
  申请人：Tonogaki Keisuke

  公开号：US20130184240A1

  公开（公告）日：2013-07-18

  Disclosed is a compound which is useful as an AMPK activator. A compound represented by the formula: its pharmaceutically acceptable salt, or a solvate thereof, wherein a group represented by the formula: is a group represented by the formula: R 1 is each independently halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or the like; m is an integer of 0 to 3; R 2 is hydrogen, or substituted or unsubstituted alkyl; X is —O—; and Y is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

  揭示了一种作为AMPK激活剂有用的化合物。一种由以下公式表示的化合物：其药学上可接受的盐，或其溶剂化合物，其中由以下公式表示的基团：是由以下公式表示的基团：R1是各自独立的卤素、羟基、氰基、硝基、羧基、取代或未取代的烷基、取代或未取代的烯烃基或类似物；m是0到3的整数；R2是氢，或取代或未取代的烷基；X是—O—；Y是取代或未取代的芳基，或取代或未取代的杂环芳基。
• Synthesis and Catalytic Applications of Multi-Walled Carbon Nanotube-Polyamidoamine Dendrimer Hybrids
  作者：Antonin Desmecht、Timothy Steenhaut、Florence Pennetreau、Sophie Hermans、Olivier Riant

  DOI：10.1002/chem.201802301

  日期：2018.9.3

  Polyamidoamine (PAMAM) dendrimers were covalently immobilized on multi‐walled carbon nanotubes (MWNT) by two “grafting to” strategies. We demonstrate the existence of non‐covalent interactions between the two components but outline the superiority of our two grafting approaches, namely xanthate and click chemistry. MWNT surfaces were functionalized with activated ester and propargylic moieties prior

  通过两种“接枝到”策略，将聚酰胺基胺（PAMAM）树状聚合物共价固定在多壁碳纳米管（MWNT）上。我们证明了这两种成分之间存在非共价相互作用，但概述了我们两种接枝方法的优势，即黄药和点击化学。在分别与PAMAM或叠氮基-PAMAM树枝状大分子反应之前，将MWNT表面用活化的酯和炔丙基官能化。使用X射线光电子能谱（XPS），热重分析（TGA）和透射电子显微镜（TEM）对0至3代PAMAM的接枝进行了评估。我们的杂种的多功能性通过涉及炔烃-叠氮化物铜环加成（CuAAC）的后功能化序列得到证明。我们在树枝状聚合物的末端合成了均相负载的铱配合物。此外，我们的材料还用作封装Pd纳米颗粒（NPS）的模板，验证了我们的纳米复合材料在催化方面的应用。钯基催化剂在连续五次运行中对羰基化偶联均具有活性，而不会损失活性。
• Arylalkylamine Compound and Process for Preparing the Same
  申请人：Miyazaki Hiroshi

  公开号：US20070225296A1

  公开（公告）日：2007-09-27

  The present invention relates to an arylalkylamine compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, a process for preparing the same, and use of the above-mentioned compound as an activating compound (CaSR agonist) of a Ca sensing receptor, a pharmaceutical composition containing the above-mentioned compound as an effective ingredient, etc. The symbols in the formula represent the following meanings: Ar: optionally substituted aryl or optionally substituted heteroaryl here, the cyclic portion of the heteroaryl is bicyclic heterocyclic ring in which 5- to 6-membered monocyclic heterocyclic ring containing 1 or 2 hetero atom(s) and benzene ring are fused; R 1 : a group selected from the group consisting of optionally substituted cyclic hydrocarbon group, and optionally substituted heterocyclic group; n: an integer of 1 to 3; X: single bonding arm, —CH 2 —, —CO—, —(CH 2 ) m —CO—, —CH(R 2 )—CO—, —(CH 2 ) p —Y—(C(R 3 )(R 4 )) q —CO—, —NH—CO— or —N(R 5 )—CO—; in the above-mentioned respective definitions of the X, the bonding arm described at the left end represents a bond with R 1 ; m is an integer of 1 to 3; p is an integer of 0 to 2; q is an integer of 0 to 2; Y: —O— or —SO 2 —; R 2 : phenyl or lower alkyl; R 3 , R 4 : each independently represents hydrogen atom or lower alkyl; R 5 : lower alkyl; provided that the ring portion of the group represented by R 1 is neither naphthylidine nor partially saturated group thereof, and, when X is —CH 2 — or —CO—, R 1 is not naphthyl.

  本发明涉及一种由以下公式[I]表示的芳基烷基胺化合物或其药学上可接受的盐，其制备方法，以及上述化合物作为钙感受受体的激活化合物（CaSR激动剂），以及含有上述化合物作为有效成分的制药组合物等的用途。公式中的符号表示以下含义：Ar：此处为可选取代的芳基或可选取代的杂环芳基，其中杂环的环部分是一个含有1或2个杂原子的5-至6元单环杂环，与苯环融合；R1：选自可选取代的环烃基团和可选取代的杂环基团的群；n：1至3的整数；X：单键臂、—CH2—、—CO—、—（ ）m—CO—、—CH（R2）—CO—、—（ ）p—Y—（C（R3）（R4））q—CO—、—NH—CO—或—N（R5）—CO—；在上述各定义的X中，左端所描述的键臂表示与R1的键；m为1至3的整数；p为0至2的整数；q为0至2的整数；Y：—O—或—SO2—；R2：苯基或低碳烷基；R3、R4：各自独立地表示氢原子或低碳烷基；R5：低碳烷基；前提是由R1表示的基团的环部分既不是萘亚甲基也不是其部分饱和基团，且当X为— —或—CO—时，R1不是萘基。